TNG:EPA
Transgene SA
0,70 €
arrow_downward
-1,96%(-0,014) 1D
2-окт., 17:35:08 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
0,70 €
High
0,70 €
Low
0,69 €
Mkt. cap
196,62 млн
Avg. vol.
140,11 миң
Volume
166,60 миң
52-wk high
1,50 €
52-wk low
0,69 €
EPS
-0,17 €
Shares outstanding
278,56 млн
No. of employees
160
Open
0,70 €
High
0,70 €
Low
0,69 €
Mkt. cap
196,62 млн
Avg. vol.
140,11 миң
Volume
166,60 миң
52-wk high
1,50 €
52-wk low
0,69 €
EPS
-0,17 €
Shares outstanding
278,56 млн
No. of employees
160
News stories
From web sources and news partners
Yahoo! Finance Canada
·
7 мүнөт мурун
AMN,HLF,PGY,BSBK,FXNC,IMRX,CRMT,MRBK,ORN,FRST,TISI,GRNT,VSTS,RVSB,GEF-B,SABR,TMCI,BCRX,DCGO,SHEN,NBBK,USCB | Stock Prices | Quote Comparison
Simply Wall Street
·
13 мүнөт мурун
3 Consumer Staples Stocks Tied To Rising Pet Care Spending
Moomoo
·
24 мүнөт мурун
October Is Here: Can the Midterm Rally Deliver Again?
The Motley Fool
·
42 мүнөт мурун
This Rare Market Signal Has Appeared Only 2 Times in a Century. Here Is What History Says Comes Next.
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA